title: [Effect of the observance of diurnal fast of Ramadan on duodenal ulcer healing with lansoprazole. Results of a prospective controlled study].
abstract: OBJECTIVE
  The aims of this study were: a) to determine whether patients with duodenal ulcer treated with a proton pump inhibitor may fast during the month of Ramadan, b) to evaluate the result of the treatment in this condition.
  
  
  METHODS
  Fifty-seven patients with acute duodenal ulcer confirmed by endoscopy were included in the study. All the patients received 30 mg lansoprazole per day during 4 weeks. After randomization, patients of group I (n = 27) were dispensed from fasting, while those of group II (n = 30) fasted. Endoscopy was performed at the end of the month of the fast.
  
  
  RESULTS
  The course of symptoms was not different in groups I and II. There were no ulcer complications. Healing rates at endoscopy were 88.8% and 90% in groups I and II, respectively. Fasting had no influence on the result of duodenal ulcer treatment by lansoprazole which was well tolerated.
  
  
  CONCLUSIONS
  Patients with duodenal ulcer treated with lansoprazole may fast without running any risk.
authors.affiliation: Sèrvice de Gastroentérologie, Hôpital Sahloul, Sousse, Tunisie.
authors.forename: A
authors.initials: A
authors.lastname: Mehdi
authors.forename: S
authors.initials: S
authors.lastname: Ajmi
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000503:physiopathology; D005215:Fasting; D005260:Female; D006801:Humans; D007514:Islam; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D009853:Omeprazole
vernacular_title: Effet du respect du jeûne diurne du Ramadan sur la cicatrisation de l'ulcère duodénal par lansoprazole. Résultats d'une étude prospective contrôlée.